Several other research firms have also weighed in on URGN. Ladenburg Thalmann Financial Services reiterated a buy rating and set a $65.00 target price on shares of Urogen Pharma in a report on Friday, March 16th. Jefferies Group reissued a buy rating on shares of Urogen Pharma in a research note on Monday, March 19th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Urogen Pharma currently has an average rating of Buy and a consensus price target of $43.33.
Urogen Pharma stock opened at $50.65 on Thursday. Urogen Pharma has a twelve month low of $13.01 and a twelve month high of $58.66.
Several institutional investors and hedge funds have recently added to or reduced their stakes in URGN. State of Tennessee Treasury Department acquired a new stake in shares of Urogen Pharma in the 3rd quarter valued at about $158,000. JPMorgan Chase & Co. acquired a new stake in shares of Urogen Pharma in the 3rd quarter valued at about $168,000. Lyon Street Capital LLC acquired a new stake in shares of Urogen Pharma in the 3rd quarter valued at about $1,316,000. GSA Capital Partners LLP acquired a new stake in shares of Urogen Pharma in the 3rd quarter valued at about $293,000. Finally, Alps Advisors Inc. raised its stake in shares of Urogen Pharma by 23.9% in the 4th quarter. Alps Advisors Inc. now owns 14,603 shares of the company’s stock valued at $543,000 after purchasing an additional 2,813 shares during the period. 50.49% of the stock is currently owned by hedge funds and other institutional investors.
WARNING: “Urogen Pharma (URGN) Rating Reiterated by Oppenheimer” was posted by Ticker Report and is the property of of Ticker Report. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3301694/urogen-pharma-urgn-rating-reiterated-by-oppenheimer.html.
About Urogen Pharma
Urogen Pharma Ltd, formerly Theracoat Ltd, is an Israel-based clinical-stage biopharmaceutical company. It is engaged in developing therapies designed to care for urological pathologies. Its lead product candidates include MitoGel and VesiGel. MiroGel is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract.
Receive News & Ratings for Urogen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urogen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.